Salud, Ciencia y Tecnología. 2025; 5:1430
doi: 10.56294/saludcyt20251430

REVIEW

The future insights of AI Applications in Hematology diseases diagnosis and prognosis: Review Article

Perspectivas futuras de las aplicaciones de IA en el diagnóstico y pronóstico de enfermedades hematológicas: artículo de revisión

Hisham Ali Waggiallah[1], Abdulkareem Al-Garni[2,3,4], Aisha Ali M Ghazwani[5], Abdulkarim S. Bin Shaya[1], Humood Al Shmrany[1], Yousif Mohammed Almosaad[6]

[1]Prince Sattam Bin Abdulaziz University, Department of Medical Laboratory Science, College of Applied Medical Science. Alkharj, Saudi Arabia.
[2]King Saud Bin Abdulaziz University for Health Science, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences. Al Hofuf, Saudi Arabia.
[3]King Abdulaziz Hospital, Ministry of National Guard-Health Affairs (MNGHA), Department of Medicine. Al-Ahsa, Saudi Arabia.
[4]King Abdullah International Medical Research Center (KAIMRC). East, Al-Ahsa, Saudi Arabia.
[5]Prince Sultan Military College of Health Sciences, Department of Clinical Laboratory Sciences. Dhahran, Saudi Arabia.
[6]King Faisal University, College of Applied Medical Sciences. Al-Hofuf, Saudi Arabia.

Cite as: Ali Waggiallah H, Al-Garni A, Ali M Ghazwani A, Bin Shaya AS, Al Shmrany H, Elmosaad Y. The future insights of AI Applications in Hematology diseases diagnosis and prognosis: Review Article. Salud, Ciencia y Tecnología. 2025; 5:1430. https://doi.org/10.56294/saludcyt20251430

Submitted: 03-12-2024 **Revised:** 12-01-2025 **Accepted:** 24-02-2025 **Published:** 25-02-2025

Editor: Prof. Dr. William Castillo-González

Corresponding author: Hisham Ali Waggiallah

ABSTRACT

Artificial intelligence (AI) is rapidly altering the field of hematology, providing novel approaches to diagnosis, prognosis, and management of hematological illnesses. AI technologies, including machine learning (ML) and deep learning (DL), allow for the analysis of massive volumes of clinical, genetic, and imaging data, resulting in more accurate, rapid, and individualized care. In diagnostic hematology, AI is transforming blood smear analysis, bone marrow aspirations, and genomic profiling by automating cell classification, detecting anomalies, and discovering critical genetic changes associated with blood illnesses. AI-powered models are also improving prognostic skills by predicting disease progression, treatment response, and risk of relapse in illnesses such as leukemia, lymphoma, anemia, and myeloproliferative disorders. Furthermore, AI applications in precision medicine enable clinicians to adapt medicines based on individual genetic profiles, thereby increasing therapeutic success and reducing unwanted effects. The combination of AI and modern technology such as wearable health monitors and real-time diagnostic tools promises to improve patient management by providing proactive care via continuous monitoring and adaptive treatment options. As AI develops, it has enormous potential in hematology, enabling early identification, optimizing treatment regimens, and ultimately improving patient survival and quality of life. This study investigates the future implications of AI applications in hematology, emphasizing their revolutionary impact on diagnosis, prognosis, and individualized treatment techniques.

Keywords: Artificial Intelligence; Hematology; CBC; Blood Film; Bone Marrow; Coagulation; Sustainable Development.

RESUMEN

La inteligencia artificial (IA) está alterando rápidamente el campo de la hematología, proporcionando nuevos enfoques para el diagnóstico, pronóstico y tratamiento de enfermedades hematológicas. Las tecnologías de IA, incluido el aprendizaje automático (ML) y el aprendizaje profundo (DL), permiten el análisis de volúmenes masivos de datos clínicos, genéticos y de imágenes, lo que da como resultado una atención más precisa, rápida e individualizada. En hematología diagnóstica, la IA está transformando el análisis de frotis de sangre, aspiraciones de médula ósea y perfiles genómicos al automatizar la clasificación celular, detectar anomalías y descubrir cambios genéticos críticos asociados con enfermedades de la sangre. Los modelos impulsados por IA también están mejorando las habilidades de pronóstico al predecir la progresión de la enfermedad, la respuesta al tratamiento y el riesgo de recaída en enfermedades como leucemia, linfoma, anemia y trastornos mieloproliferativos. Además, las aplicaciones de IA en la medicina de precisión permiten a los médicos adaptar los medicamentos en función de los perfiles genéticos individuales, lo que aumenta el éxito terapéutico y reduce los efectos no deseados. La combinación de IA y tecnología moderna, como monitores de salud portátiles y herramientas de diagnóstico en tiempo real, promete mejorar la gestión de los pacientes al brindar atención proactiva a través de un monitoreo continuo y opciones de tratamiento adaptativo. A medida que la IA se desarrolla, tiene un enorme potencial en hematología, permitiendo la identificación temprana, optimizando los regímenes de tratamiento y, en última instancia, mejorando la supervivencia y la calidad de vida de los pacientes. Este estudio investiga las implicaciones futuras de las aplicaciones de IA en hematología, enfatizando su impacto revolucionario en el diagnóstico, el pronóstico y las técnicas de tratamiento individualizadas.

Palabras clave: Inteligencia Artificial; Hematología; CSC, Frotis De Sangre; Médula Ósea; Coagulación; Desarrollo Sostenible.

INTRODUCTION

Hematology, the branch of medicine that studies blood, blood-forming organs, and hematologic illnesses, has advanced significantly throughout the years. Traditional methods of detecting and managing hematologic illnesses, such as blood smears, bone marrow aspiration, and genetic testing, have relied significantly on the knowledge and experience of physicians and pathologists. While these methods have proven essential, they frequently have limitations in terms of speed, accuracy, and scalability, especially when dealing with massive amounts of data or complex illness patterns. In this context, Artificial Intelligence (AI) is poised to transform hematology, bringing new, efficient techniques to diagnose, monitor, and treat hematologic illnesses.[1]

AI applications, particularly those based on machine learning (ML) and deep learning (DL) algorithms, have unparalleled capabilities for analyzing large datasets from a wide range of sources, including medical imaging, electronic health records (EHRs), genomic profiles, and laboratory results. These technologies enable the automation of complicated activities such as blood cell classification, illness pattern detection, and predictive modeling, which are traditionally labor-intensive and prone to human error. Hematologists can use AI to make faster, more accurate diagnoses, identify disease progression early, and personalize treatment approaches based on specific patient profiles. The potential of artificial intelligence in hematology extends beyond diagnosis. AI is also useful in the prognosis of hematologic disorders, providing methods to predict illness outcomes, relapse risks, and responses to treatment. This predictive power allows clinicians to better personalize medicines, optimizing treatment regimens and increasing patient survival rates. For example, in leukemia, AI may assess genetic alterations, bone marrow imaging, and clinical data to estimate a patient's likelihood of remission or relapse, thereby directing therapeutic options. Similarly, AI can evaluate the severity of blood problems such as anemia and myeloproliferative diseases and offer individualized therapies. As AI technologies progress, the incorporation of these tools into hematology practices promises to not only improve diagnostic accuracy and prognostic foresight, but also bring about a paradigm shift in the way hematologic disorders are treated and managed. This study investigates the future of AI applications in hematology, emphasizing its potential to transform illness diagnosis, prognosis, and individualized treatment options. Through continued breakthroughs in AI, the future of hematology holds great promise for improving patient outcomes, making healthcare more efficient, and enabling tailored, data-driven method.[1,2]

The Role of AI in Enhancing Complete Blood Count (CBC) Analysis

A complete blood count (CBC) is one of the most popular diagnostic tests used in clinical practice to assess a person's overall health and diagnose a wide range of illnesses, including infections, anemia, clotting abnormalities, and leukemia. However, the introduction of Artificial Intelligence (AI) has greatly enhanced the accuracy, speed, and efficiency of CBC interpretation, revolutionizing both laboratory and clinical settings. AI technologies, notably machine learning (ML) and deep learning (DL), are currently being integrated into CBC analysis to deliver more accurate, trustworthy, and timely diagnostic information.[3]

Automated Blood Cell Classification and Counting

One of the most important uses of AI in CBC analysis is the automation of blood cell counts and classification. Traditional CBC machines count blood cells using optical or electrical impedance methods, with laboratory staff manually interpreting the results. While these procedures are successful, they are susceptible to errors caused by human factors such as misinterpretation or inconsistent analysis, particularly when dealing with aberrant cell morphology or low-quality blood samples.

AI-powered systems, particularly those that employ machine learning algorithms, can analyze blood smear images and automate the process of recognizing and classifying various types of blood cells (RBCs, WBCs, platelets, and so on). Convolutional Neural Networks (CNNs), a sort of deep learning model, have proven particularly successful in this area. CNNs may be trained on massive datasets of labeled blood smear pictures, enabling them to learn the minute differences between cell types. After training, the AI system can correctly recognize and categorize cells from blood samples, considerably enhancing the efficiency and accuracy of CBC analysis.

Detection of Abnormalities and Pathologies

AI can help discover abnormalities or illnesses that the human eye may miss. Many hematological illnesses, including leukemia, lymphoma, and other blood malignancies, exhibit subtle or complicated changes in blood cell shape. In typical practice, a pathologist or hematologist examines blood smears under a microscope to detect abnormalities, although this can be time-consuming and prone to error.

AI-powered systems may automatically identify aberrant blood cells with high precision by assessing differences in cell size, shape, and structure, as well as other minor indicators like the presence of inclusions or abnormalities.

Predictive Analysis and Risk Stratification

AI can also be used to forecast patient outcomes and aid in risk stratification using CBC data. Machine learning algorithms can find patterns in big datasets of patient information, such as CBC results, demographic data, medical history, and clinical outcomes that may suggest the likelihood of developing specific disorders or diseases. For example, AI systems can forecast a patient's risk of getting anemia, sepsis, or even cancer based on minor changes in their CBC over time. These prediction models can assist doctors in proactively monitoring at-risk patients, allowing for earlier interventions and individualized treatment approaches. Furthermore, AI-based risk prediction technologies can provide useful insights to public health initiatives and disease surveillance by identifying trends and patterns within populations.[4]

Integration with Other Diagnostic Tools

When combined with additional diagnostic techniques like genetic testing, imaging, and clinical decision support systems, AI has the potential to greatly increase the value of CBC. Combining CBC data with results from other diagnostic tests, such as PCR tests, genetic sequencing, or radiology reports, provides a more complete picture of a patient's condition.

For example, AI can combine CBC data with genomic data to predict the genetic basis of specific blood illnesses, such as hemoglobinopathies, or to detect mutations that may indicate a vulnerability to certain blood malignancies. Furthermore, combining CBC data with imaging technologies such as CT scans or MRIs, can help provide a more accurate diagnosis in cases of suspected hematologic malignancies or other complex illnesses.

AI also helps to ensure that CBC findings are accurate and consistent. Inconsistencies in manual blood sample analysis might be caused by human error, sample contamination, or device calibration difficulties.[3,4]

The Role of AI in Blood Smear Analysis

Blood smear analysis is an important diagnostic method in hematology, in which laboratory professionals examine a thin layer of blood on a slide under a microscope to identify and classify different blood cells. This approach aids in the diagnosis of a wide range of blood illnesses, including anemia, infections, and hematological cancers such as leukemia. However, standard blood smear examination can be time-consuming, reliant on laboratory worker competence, and prone to human error, particularly when dealing with complicated or aberrant cell morphologies. AI integration in blood smear analysis provides various benefits, including improved accuracy, efficiency, and the ability to handle enormous amounts of data. Below are some of the primary ways AI is used in blood smear analysis:

Automated Blood Cell Identification and Classification

One of AI's most important contributions to blood smear analysis is the automation of blood cell identification and classification. Traditionally, a hematologist or technician examines a blood smear under a microscope to detect various blood cell types. This procedure is not only time-consuming, but also prone to human tiredness

https://doi.org/10.56294/saludcyt20251430

and inaccuracy, especially if the blood smear contains a large number of cells or aberrant cell types. Artificial intelligence, notably deep learning algorithms, can interpret blood smear images in a quarter of the time. AI can automatically detect and classify blood cells, considerably accelerating the procedure and lowering the chance of misclassification.[5]

Abnormal Cell Detection and Disease Diagnosis

One of the most difficult aspects of blood smear examination is recognizing abnormal or atypical cells, which might signify serious medical disorders such as blood malignancies (e.g., leukemia) or infections. AI improves our ability to detect these problems with high sensitivity and specificity. Deep learning algorithms can analyze the size, shape, texture, and color of individual blood cells and detect tiny abnormalities that may not be immediately visible to the human eye.[6]

Assistive Tools for Pathologists and Hematologists

AI in blood smear analysis is not designed to replace medical personnel, but rather to enhance their workflow and decision-making. AI can speed up the process by automating repetitive processes like cell identification, categorization, and counting, freeing pathologists to focus on more complicated elements of diagnosis. AI can also provide second opinions or identify potential areas of concern, minimizing the chance of missed diagnoses.[7]

Integration with Other Diagnostic Data

AI-powered blood smear analysis can be combined with other diagnostic tools like CBC data, patient history, radiology, and genetic testing. Combining data from many sources allows AI to deliver a more comprehensive diagnosis and better disease prediction.[8]

The Role of AI in Bone Marrow Aspiration Analysis

Bone marrow aspiration is an important diagnostic procedure for examining the marrow, which is the spongy substance inside bones that produces blood cells. This method is commonly used to diagnose a variety of hematologic illnesses, including leukemia, lymphoma, anemia, and myeloproliferative disorders. Traditionally, bone marrow aspirations were analyzed manually by pathologists, who examined the samples under a microscope to determine cell shape, count different types of cells, and detect any abnormalities. However, this approach can be time-consuming, subjective, and prone to human error, especially when dealing with complicated or subtle pathologies.[9]

The incorporation of artificial intelligence (AI) has the potential to transform how bone marrow aspirations are assessed. AI can improve the quality, efficiency, and reproducibility of bone marrow aspiration analysis, giving pathologists useful decision-support tools and allowing for faster, more accurate diagnosis. Here, we investigate the many applications and benefits of AI in bone marrow aspiration analysis.[10]

Detection of Abnormalities and Pathologies

Bone marrow aspiration is frequently used to diagnose several hematological diseases, including:

AI can detect the presence of immature or blast cells, which are typical with acute leukemias. AI can aid in the detection of dysplastic alterations in blood cells, such as aberrant nuclear shapes, which are indicative of disease.

Bone Marrow Hyperplasia or Hypoplasia: AI models can evaluate the cellularity of bone marrow samples, detecting either increased (hyperplasia) or decreased cellularity (hypoplasia), which can indicate illnesses such as anemia or aplastic anemia.

Clonal Disorders: AI can assess the shape of blood cells to detect monoclonal populations, which are frequently associated with hematologic cancers such as multiple myeloma or lymphomas.

Fibrosis: Artificial intelligence can be used to diagnose bone marrow fibrosis, which is characterized by aberrant marrow scarring and can arise in illnesses such as myelofibrosis or chronic leukemia.

AI's capacity to detect these irregularities in real time enables faster diagnosis and more accurate disease identification, which is critical for timely treatment initiation.[11]

Quantification and Monitoring of Cell Populations

Accurate measurement of various blood cell types is critical for diagnosing and monitoring numerous hematological disorders. AI-powered systems can automatically count distinct cell types in bone marrow samples, offering more consistent and exact results than manual approaches. AI can count the amount of blast cells in a leukemia sample, monitor the distribution of RBC precursors in anemia, and detect specific aberrant cell populations. This automated counting assists pathologists to spot trends and abnormalities, such as:

- Increased or decreased cell counts in specific cell populations (for example, blasts in leukemia or megakaryocytes in thrombocytopenia).

- Higher reticulocyte numbers in circumstances such as hemolysis or blood loss.
- Observing changes in cell populations over time to assess illness progression or response to treatment.

By precisely quantifying cell populations, AI systems can help pathologists follow disease progression or remission and assure timely interventions.(12)

Prognostic Modeling

In addition to diagnostic analysis, AI can be used to create prognostic models that predict illness outcomes using bone marrow aspiration results. AI systems can discover similarities in big datasets of aspiration pictures and clinical data that may suggest the likelihood of illness progression or remission.(13)

AI can predict the likelihood of relapse in leukemia patients depending on the amount of blast cells or other characteristics found in the bone marrow sample. Similarly, AI models can assist in risk classification for patients with myelodysplastic syndromes, allowing doctors to make better educated treatment decisions.(14)

The role of AI in diagnosis and prognosis coagulation diseases

Coagulation disorders are often diagnosed using a combination of laboratory tests that look at clotting factors, platelet function, and how long it takes for blood to clot. However, the diagnosis, treatment, and prognosis of coagulation diseases remain difficult, with many cases including a high level of clinical ambiguity. Current diagnostic techniques rely mainly on traditional laboratory testing, clinical observations, and expert judgment, which, although useful, can be sluggish, wasteful, and prone to human error. Artificial intelligence (AI) is emerging as a transformative tool in enhancing the accuracy, speed, and personalization of coagulation disorder diagnosis and prognosis.(15)

AI can identify underlying patterns that humans may find difficult or impossible to detect. These algorithms can detect anomalies in blood clotting, forecast probable problems, and provide individualized therapy recommendations based on unique patient characteristics. AI's purpose in identifying coagulation disorders is not just to increase speed, but also to improve clinical accuracy, ensuring that diagnoses are based on the most thorough data available.(16)

AI's future in coagulation diseases depends on its capacity to aid in earlier and more precise detection. Hemophilia, a genetic bleeding illness, can be identified more rapidly using AI technologies that examine genomic data and coagulation test results. Similarly, von Willebrand disease (vWD), AI's role in understanding rare, complex coagulation disorders—such as thrombophilia (a predisposition to abnormal clotting) and DIC (a condition involving widespread clotting and bleeding), can enable more precise division of patient risk and prognosis, resulting to improved management and effects.(17)

Beyond diagnosis, AI shows promise in predicting the progression and treatment of coagulation diseases. Many coagulation illnesses require lifetime treatment, and predicting disease progression can be extremely difficult. Traditional methods of monitoring patients with clotting problems rely on periodic blood tests and clinical assessments, which can be time-consuming and may not always accurately reflect a patient's current condition. AI algorithms can track a patient's coagulation profile over time, forecast probable consequences like bleeding episodes in hemophilia or thrombotic events in thrombophilia, and assist physicians in making appropriate adjustments to treatment plans. Using predictive modeling techniques, AI can foresee the likelihood of adverse events linked with aberrant clotting tendencies, such as stroke or venous thromboembolism (VTE), allowing for more proactive, individualized treatment options.(18)

One important feature of individualized treatment that AI improves is the utilization of patient-specific data to inform therapeutic decisions. For example, in hemophilia care, AI can combine genetic data, bleeding history, and previous treatment responses to assist clinicians in determining the most effective medication, whether factor replacement therapy or gene therapy. In patients with DIC, AI systems may monitor coagulation markers in real time to determine the stage of the disorder (acute vs. chronic) and recommend the optimal course of action, including whether anticoagulants or clotting factor replacement should be prioritized. AI-powered systems can also help in determining the optimum amount of pharmaceuticals, ensuring that patients receive optimal therapy while minimizing the risk of bad effects.

Additionally, AI has the potential to improve our understanding of the underlying pathophysiology of coagulation diseases. AI can aid in the identification of novel biomarkers and the discovery of previously undisclosed genetic mutations or environmental factors that contribute to coagulation dysfunction by analyzing big clinical datasets that include laboratory testing, genetic markers and patient outcomes. These findings can lead to more precise diagnostic criteria, improved risk stratification tools, and the development of new, focused treatments.(19)

https://doi.org/10.56294/saludcyt20251430

Real-time Analysis and Telemedicine

In distant or underdeveloped locations, where access to specialized hematologists is limited, AI-powered blood smear analysis can provide real-time diagnostic support via telemedicine. All hematological investigations can be digitized and analyzed with AI algorithms, allowing healthcare providers to exchange findings with distant experts who can provide comments and assistance.[20,21,22,23] This feature is especially valuable in emergency scenarios or rural healthcare settings where prompt access to specialized medical treatment is vital. AI-powered blood smear analysis can help bridge the gap, allowing for faster diagnosis and early therapies.

AI in Drug Discovery and Hematology Research

The use of AI in drug discovery is hastening the development of new treatments for hematological illnesses. AI can find prospective drug candidates and predict their success in treating specific hematological disorders by analyzing massive datasets that include genetic, proteomic, and pharmacological data.[24,25,26,27]

Artificial intelligence (AI) has emerged as a disruptive force in hematology, transforming disease diagnosis and prediction while also harmonizing with the Sustainable Development Goals. AI specifically promotes SDG 3 (Good Health and Well-being) by enhancing early detection and illness management, reducing mortality and morbidity associated with disorders such as leukemia, anemia, and thrombocytopenia.[28]

CONCLUSION

In conclusion, AI has enormous potential to revolutionize the diagnosis and prognosis of hematopoietic disorders. By leveraging machine learning and deep learning, AI can increase diagnosis accuracy, forecast disease progression, and tailor treatment strategies, resulting in significant improvements in patient outcomes. As AI advances, its integration into hematology practice will result in more efficient, precise, and timely care, eventually altering how hematologic disorders are managed. With continued improvements and correct application, AI will play a vital role in creating the future of hematology, bringing new hope for both patients and healthcare practitioners.

REFERENCES

1. Radakovich N, Nagy M, Nazha A. Artificial Intelligence in Hematology: Current Challenges and Opportunities. Curr Hematol Malig Rep. 2020 Jun;15(3):203-210. doi: 10.1007/s11899-020-00575-4. PMID: 32239350.

2. Kather JN. Artificial intelligence in oncology: chances and pitfalls. J Cancer Res Clin Oncol. 2023 Aug;149(10):7995-7996. doi: 10.1007/s00432-023-04666-6. Epub 2023 Mar 15. PMID: 36920564; PMCID: PMC10374782.

3. Shimizu H, Nakayama KI. Artificial intelligence in oncology. Cancer Sci. 2020 May;111(5):1452-1460. doi: 10.1111/cas.14377. Epub 2020 Mar 21. PMID: 32133724; PMCID: PMC7226189.

4. Alanzi T, Alanazi F, Mashhour B, Altalhi R, Alghamdi A, Al Shubbar M. Surveying Hematologists' Perceptions and Readiness to Embrace Artificial Intelligence in Diagnosis and Treatment Decision-Making. Cureus. 2023 Nov 26;15(11):e49462. doi: 10.7759/cureus.49462. PMID: 38152821; PMCID: PMC10751460.

5. Mohammed EA, Mohamed MM, Far BH, Naugler C. Peripheral blood smear image analysis: A comprehensive review. J Pathol Inform. 2014 Mar 28;5(1):9. doi: 10.4103/2153-3539.129442. PMID: 24843821; PMCID: PMC4023032.

6. KATZ, Ben Zion, et al. A Novel Approach to Blood Smear Analysis Based on Specimen Topology: Implications for Human and Artificial Intelligence Decision Making. Blood, 2020, 136: 8-9.

7. Cheng W, Liu J, Wang C, Jiang R, Jiang M, Kong F. Application of image recognition technology in pathological diagnosis of blood smears. Clin Exp Med. 2024 Aug 6;24(1):181. doi: 10.1007/s10238-024-01379-z. PMID: 39105953; PMCID: PMC11303489.

8. Shams UA, Javed I, Fizan M, Shah AR, Mustafa G, Zubair M, Massoud Y, Mehmood MQ, Naveed MA. Bio-net dataset: AI-based diagnostic solutions using peripheral blood smear images. Blood Cells Mol Dis. 2024 Mar;105:102823. doi: 10.1016/j.bcmd.2024.102823. Epub 2024 Jan 4. PMID: 38241949.

9. van Eekelen L, Litjens G, Hebeda KM. Artificial Intelligence in Bone Marrow Histological Diagnostics: Potential Applications and Challenges. Pathobiology. 2024;91(1):8-17. doi: 10.1159/000529701. Epub 2023 Feb 15. PMID: 36791682; PMCID: PMC10937040.

10. Ghete T, Kock F, Pontones M, Pfrang D, Westphal M, Höfener H, Metzler M. Models for the marrow: A comprehensive review of AI-based cell classification methods and malignancy detection in bone marrow aspirate smears. Hemasphere. 2024 Dec 3;8(12):e70048. doi: 10.1002/hem3.70048. PMID: 39629240; PMCID: PMC11612571.

11. Fervers P, Fervers F, Kottlors J, Lohneis P, Pollman-Schweckhorst P, Zaytoun H, et al. Feasibility of artificial intelligence-supported assessment of bone marrow infiltration using dual-energy computed tomography in patients with evidence of monoclonal protein - a retrospective observational study. Eur Radiol. 2022 May;32(5):2901-2911. doi: 10.1007/s00330-021-08419-2. Epub 2021 Dec 18. PMID: 34921619; PMCID: PMC9038860.

12. Tang G, Fu X, Wang Z, Chen M. A Machine Learning Tool Using Digital Microscopy (Morphogo) for the Identification of Abnormal Lymphocytes in the Bone Marrow. Acta Cytol. 2021;65(4):354-357. doi: 10.1159/000518382. Epub 2021 Jul 20. PMID: 34350848.

13. Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Jauch A, Hajiyianni M, et al. Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3697-3708. doi: 10.1007/s00259-023-06339-5. Epub 2023 Jul 26. PMID: 37493665; PMCID: PMC10547616.

14. Bagg A, Raess PW, Rund D, Bhattacharyya S, Wiszniewska J, Horowitz A, Jengehino D, Fan G, Huynh M, Sanogo A, Avivi I, Katz BZ. Performance Evaluation of a Novel Artificial Intelligence-Assisted Digital Microscopy System for the Routine Analysis of Bone Marrow Aspirates. Mod Pathol. 2024 Sep;37(9):100542. doi: 10.1016/j.modpat.2024.100542. Epub 2024 Jun 17. PMID: 38897451.

15. Wang R, Tang LV, Hu Y. Genetic factors, risk prediction and AI application of thrombotic diseases. Exp Hematol Oncol. 2024 Aug 27;13(1):89. doi: 10.1186/s40164-024-00555-x. PMID: 39192370; PMCID: PMC11348605.

16. Rashidi HH, Bowers KA, Reyes Gil M. Machine learning in the coagulation and hemostasis arena: an overview and evaluation of methods, review of literature, and future directions. J Thromb Haemost. 2023 Apr;21(4):728-743. doi: 10.1016/j.jtha.2022.12.019. Epub 2022 Dec 28. PMID: 36696218.

17. Mohammadi Aria M, Erten A, Yalcin O. Technology Advancements in Blood Coagulation Measurements for Point-of-Care Diagnostic Testing. Front Bioeng Biotechnol. 2019 Dec 11;7:395. doi: 10.3389/fbioe.2019.00395. PMID: 31921804; PMCID: PMC6917661.

18. Wang W, Zeng W, Yang S. A stacked machine learning-based classification model for endometriosis and adenomyosis: a retrospective cohort study utilizing peripheral blood and coagulation markers. Front Digit Health. 2024 Sep 10;6:1463419. doi: 10.3389/fdgth.2024.1463419. PMID: 39347446; PMCID: PMC11428011.

19. Guo K, Fu X, Zhang H, Wang M, Hong S, Ma S. Predicting the postoperative blood coagulation state of children with congenital heart disease by machine learning based on real-world data. Transl Pediatr. 2021 Jan;10(1):33-43. doi: 10.21037/tp-20-238. PMID: 33633935; PMCID: PMC7882284.

20. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database (Oxford). 2020 Jan 1;2020:baaa010. doi: 10.1093/database/baaa010. PMID: 32185396; PMCID: PMC7078068.

21. Lococo F, Ghaly G, Chiappetta M, Flamini S, Evangelista J, Bria E, et al. Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review. Cancers (Basel). 2024 May 10;16(10):1832. doi: 10.3390/cancers16101832. PMID: 38791910; PMCID: PMC11119930.

22. Fawaz A, Ferraresi A, Isidoro C. Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making. J Pers Med. 2023 Nov 10;13(11):1590. doi: 10.3390/jpm13111590. PMID: 38003905; PMCID: PMC10672164.

23. Giri AK, Ianevski A. High-throughput screening for drug discovery targeting the cancer cell-microenvironment interactions in hematological cancers. Expert Opin Drug Discov. 2022 Feb;17(2):181-190. doi: 10.1080/17460441.2022.1991306. Epub 2021 Nov 8. PMID: 34743621.

24. Singh K, Singh A. Artificial intelligence in hematology: A critical perspective. J Clin Exp Hematol. 2024;3(1):60-66.

25. Wang SX, Huang ZF, Li J, Wu Y, Du J, Li T. Optimization of diagnosis and treatment of hematological diseases via artificial intelligence. Front Med (Lausanne). 2024 Nov 7;11:1487234. doi: 10.3389/fmed.2024.1487234. PMID: 39574909; PMCID: PMC11578717.

26. Zini G. Artificial intelligence in hematology. Hematology. 2005 Oct;10(5):393-400. doi: 10.1080/10245330410001727055. PMID: 16203606.

27. Radakovich N, Nagy M, Nazha A. Artificial Intelligence in Hematology: Current Challenges and Opportunities. Curr Hematol Malig Rep. 2020 Jun;15(3):203-210. doi: 10.1007/s11899-020-00575-4. PMID: 32239350.

28. Garg H, Kashif M, Sharma P, Singhal N. Innovating Global Health With Smart Technology to Achieve Sustainable Development. In: Driving Global Health and Sustainable Development Goals With Smart Technology. IGI Global Scientific Publishing, 2025. p. 11-36.

FINANCING
The authors extend their appreciation to Prince Sattam bin Abdulaziz University for funding this research work through the project number (PSAU/2024/03/31838).

CONFLICT OF INTEREST
Author declared that there is no conflict of interest in this research

AUTHORSHIP CONTRIBUTION
Conceptualization: Hisham Ali Waggiallah.
Data curation: Abdulkareem Al-Garni, Abdulkarim S. Bin Shaya.
Formal analysis: Hisham Ali Waggiallah, Yousif Mohammed Almosaad.
Research: Aisha Ali M Ghazwani, Abdulkarim S. Bin Shaya.
Project management: Hisham Ali Waggiallah.
Resources: Abdulkareem Al-Garni, Humood Al Shmrany.
Software: Yousif Mohammed Almosaad.
Supervision: Hisham Ali Waggiallah.
Validation: Aisha Ali M Ghazwani, Humood Al Shmrany.
Drafting - original draft: Hisham Ali Waggiallah, Abdulkareem Al-Garni.